相关实验视频

Updated: Jun 9, 2025

Predictive Immune Modeling of Solid Tumors

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

一个多奥米克预后模型捕捉瘤干和清细胞脏细胞癌中的免疫微环境

Beibei Xiong¹, Wenqiang Liu², Ying Liu²

¹Department of Oncology, The First People's Hospital of Shuangliu District, Chengdu 610200, China.

|October 26, 2024

概括

癌症干细胞 (CSCs) 驱动清细胞细胞癌 (ccRCC) 的进展和治疗阻力. 识别CRCS1和CRCS2亚型有助于预测患者的结果和指导向治疗.

科学领域:

在瘤学瘤学.
癌症干细胞生物学
细胞癌研究细胞癌研究

背景情况:

癌症干细胞 (CSCs) 参与瘤抵抗,转移和自我更新.
了解清细胞细胞癌 (ccRCC) 中的CSC对于治疗疗效和耐药性至关重要.
确定CSC属性对于推进瘤治疗至关重要.

研究的目的:

根据CSC属性识别和描述ccRCC的新型分子亚型.
研究这些亚型,瘤微环境和治疗反应之间的关系.
为ccRCC患者的治疗结果,复发和耐药性开发预后模型.

主要方法:

无监督聚类确定了两个分子亚型:CRCS1和CRCS2.
分析包括瘤免疫环境,代谢活动,疾病进展和免疫治疗反应.
评估了基因组变化,临床表现和药物反应可能性.

主要成果:

与CRCS1相比,CRCS2患者的预后更好,临床阶段/分级较低.
在低氧状态下,CRCS2显示免疫抑制/排斥,对特定向疗法敏感.
一个预后风险模型准确地预测了结果,复发和耐药性.
SAA2被确定为一种影响瘤进展的新型治疗标.

结论:

CSCs显著影响ccRCC瘤微环境,影响治疗策略.
瘤干性特征是预测治疗疗效,复发和耐药性的关键.
研究结果为ccRCC治疗研究和临床管理提供了关键的见解.

关键词:

癌症类似干细胞的细胞.免疫微型环境的免疫.预测模型的预测模型.细胞癌瘤是细胞癌.

更多相关视频

Microfluidic Co-culture of Renal Healthy and Tumor Epithelium to Model Kidney Cancer Progression

Microfluidic Co-culture of Renal Healthy and Tumor Epithelium to Model Kidney Cancer Progression

Published on: January 31, 2025

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Published on: February 8, 2018

相关概念视频

The Tumor Microenvironment

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...

Cancer Stem Cells and Tumor Maintenance

Cancer Stem Cells and Tumor Maintenance

Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...